A single-centre, multiple-dose trial to investigate the efficacy, tolerability and pharmacokinetics of dalbavancin in volunteers.

Trial Profile

A single-centre, multiple-dose trial to investigate the efficacy, tolerability and pharmacokinetics of dalbavancin in volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jan 2015

At a glance

  • Drugs Dalbavancin (Primary)
  • Indications Bacterial infections; Gram-positive infections
  • Focus Adverse reactions
  • Most Recent Events

    • 07 May 2013 New trial record
    • 29 Apr 2013 Results were reported in a Durata Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top